Cargando…
Allopregnanolone-based treatments for postpartum depression: Why/how do they work?
Recent FDA approval of an allopregnanolone-based treatment specifically for postpartum depression, brexanolone, now commercially called Zulresso®, is an exciting development for patients and families impacted by postpartum depression and allows us to start asking questions about why and how this com...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838978/ https://www.ncbi.nlm.nih.gov/pubmed/31709278 http://dx.doi.org/10.1016/j.ynstr.2019.100198 |